Filtered By:
Countries: New Zealand Health
This page shows you your search results in order of date. This is page number 12.
Order by Relevance | Date
Total 442 results found since Jan 2013.
A quality improvement project to improve access to stroke clot retrieval from a regional stroke centre
N Z Med J. 2022 Aug 19;135(1560):117-119.ABSTRACTNil.PMID:35999806
Source: New Zealand Medical Journal - August 24, 2022 Category: General Medicine Authors: Karim M Mahawish Muir Wallace Source Type: research
The unexpected benefits of sodium glucose co-transporter 2 (SGLT2) Inhibitors
N Z Med J. 2022 Aug 19;135(1560):99-104.ABSTRACTThe sodium glucose co-transporter 2 (SGLT2) inhibitor empagliflozin is currently funded in New Zealand for management of patients with type 2 diabetes who have an HbA1c >53mmol/mol and a high cardiovascular (CV) risk. Large clinical trials now provide strong evidence that SGLT2 inhibitors decrease the risk of cardiovascular death, heart failure, progressive kidney dysfunction, myocardial infarction, stroke and gout. Patients with or without diabetes who have a history of heart failure, including those with a preserved left ventricular ejection fraction and patients with ch...
Source: New Zealand Medical Journal - August 24, 2022 Category: General Medicine Authors: Chok G Chan Ralph Stewart Source Type: research
Trends in the service provision and patient outcomes from 2013 to 2021 at a regional stroke centre
N Z Med J. 2022 Aug 19;135(1560):120-124.ABSTRACTNil.PMID:35999807
Source: New Zealand Medical Journal - August 24, 2022 Category: General Medicine Authors: Karim M Mahawish Source Type: research
A quality improvement project to improve access to stroke clot retrieval from a regional stroke centre
N Z Med J. 2022 Aug 19;135(1560):117-119.ABSTRACTNil.PMID:35999806
Source: New Zealand Medical Journal - August 24, 2022 Category: General Medicine Authors: Karim M Mahawish Muir Wallace Source Type: research
The unexpected benefits of sodium glucose co-transporter 2 (SGLT2) Inhibitors
N Z Med J. 2022 Aug 19;135(1560):99-104.ABSTRACTThe sodium glucose co-transporter 2 (SGLT2) inhibitor empagliflozin is currently funded in New Zealand for management of patients with type 2 diabetes who have an HbA1c >53mmol/mol and a high cardiovascular (CV) risk. Large clinical trials now provide strong evidence that SGLT2 inhibitors decrease the risk of cardiovascular death, heart failure, progressive kidney dysfunction, myocardial infarction, stroke and gout. Patients with or without diabetes who have a history of heart failure, including those with a preserved left ventricular ejection fraction and patients with ch...
Source: New Zealand Medical Journal - August 24, 2022 Category: General Medicine Authors: Chok G Chan Ralph Stewart Source Type: research
Trends in the service provision and patient outcomes from 2013 to 2021 at a regional stroke centre
N Z Med J. 2022 Aug 19;135(1560):120-124.ABSTRACTNil.PMID:35999807
Source: New Zealand Medical Journal - August 24, 2022 Category: General Medicine Authors: Karim M Mahawish Source Type: research
A quality improvement project to improve access to stroke clot retrieval from a regional stroke centre
N Z Med J. 2022 Aug 19;135(1560):117-119.ABSTRACTNil.PMID:35999806
Source: New Zealand Medical Journal - August 24, 2022 Category: General Medicine Authors: Karim M Mahawish Muir Wallace Source Type: research
The unexpected benefits of sodium glucose co-transporter 2 (SGLT2) Inhibitors
N Z Med J. 2022 Aug 19;135(1560):99-104.ABSTRACTThe sodium glucose co-transporter 2 (SGLT2) inhibitor empagliflozin is currently funded in New Zealand for management of patients with type 2 diabetes who have an HbA1c >53mmol/mol and a high cardiovascular (CV) risk. Large clinical trials now provide strong evidence that SGLT2 inhibitors decrease the risk of cardiovascular death, heart failure, progressive kidney dysfunction, myocardial infarction, stroke and gout. Patients with or without diabetes who have a history of heart failure, including those with a preserved left ventricular ejection fraction and patients with ch...
Source: New Zealand Medical Journal - August 24, 2022 Category: General Medicine Authors: Chok G Chan Ralph Stewart Source Type: research
Trends in the service provision and patient outcomes from 2013 to 2021 at a regional stroke centre
N Z Med J. 2022 Aug 19;135(1560):120-124.ABSTRACTNil.PMID:35999807
Source: New Zealand Medical Journal - August 24, 2022 Category: General Medicine Authors: Karim M Mahawish Source Type: research
A quality improvement project to improve access to stroke clot retrieval from a regional stroke centre
N Z Med J. 2022 Aug 19;135(1560):117-119.ABSTRACTNil.PMID:35999806
Source: New Zealand Medical Journal - August 24, 2022 Category: General Medicine Authors: Karim M Mahawish Muir Wallace Source Type: research
Trends in the service provision and patient outcomes from 2013 to 2021 at a regional stroke centre
N Z Med J. 2022 Aug 19;135(1560):120-124.ABSTRACTNil.PMID:35999807
Source: New Zealand Medical Journal - August 24, 2022 Category: General Medicine Authors: Karim M Mahawish Source Type: research
A quality improvement project to improve access to stroke clot retrieval from a regional stroke centre
N Z Med J. 2022 Aug 19;135(1560):117-119.ABSTRACTNil.PMID:35999806
Source: New Zealand Medical Journal - August 24, 2022 Category: General Medicine Authors: Karim M Mahawish Muir Wallace Source Type: research
The unexpected benefits of sodium glucose co-transporter 2 (SGLT2) Inhibitors
N Z Med J. 2022 Aug 19;135(1560):99-104.ABSTRACTThe sodium glucose co-transporter 2 (SGLT2) inhibitor empagliflozin is currently funded in New Zealand for management of patients with type 2 diabetes who have an HbA1c >53mmol/mol and a high cardiovascular (CV) risk. Large clinical trials now provide strong evidence that SGLT2 inhibitors decrease the risk of cardiovascular death, heart failure, progressive kidney dysfunction, myocardial infarction, stroke and gout. Patients with or without diabetes who have a history of heart failure, including those with a preserved left ventricular ejection fraction and patients with ch...
Source: New Zealand Medical Journal - August 24, 2022 Category: General Medicine Authors: Chok G Chan Ralph Stewart Source Type: research
